Lung function trajectories in patients with idiopathic pulmonary fibrosis

被引:7
|
作者
Neely, Megan L. [1 ,2 ]
Hellkamp, Anne S. [1 ,2 ]
Bender, Shaun [3 ]
Todd, Jamie L. [1 ,2 ]
Liesching, Timothy [4 ]
Luckhardt, Tracy R. [5 ]
Oldham, Justin M. [6 ]
Raj, Rishi [7 ]
White, Eric S. [3 ]
Palmer, Scott M. [1 ,2 ]
机构
[1] Duke Clin Res Inst, Durham, NC 27701 USA
[2] Duke Univ, Med Ctr, Durham, NC 27710 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[4] Lahey Hosp & Med Ctr, Burlington, MA USA
[5] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[7] Stanford Univ, Sch Med, Stanford, CA USA
关键词
Interstitial lung disease; Lung function testing; Forced vital capacity; FORCED VITAL CAPACITY; CLINICAL-COURSE; INTERSTITIAL PNEUMONIA; SURVIVAL; PROGRESSION; MORTALITY; PIRFENIDONE; SPIROMETRY; NINTEDANIB; EFFICACY;
D O I
10.1186/s12931-023-02503-5
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.Methods Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns. Results Of 1002 patients in the registry, 941 had = 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.Conclusions Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Lung function trajectories in patients with idiopathic pulmonary fibrosis
    Megan L Neely
    Anne S Hellkamp
    Shaun Bender
    Jamie L Todd
    Timothy Liesching
    Tracy R Luckhardt
    Justin M Oldham
    Rishi Raj
    Eric S White
    Scott M Palmer
    Respiratory Research, 24
  • [2] Lung Function Trajectories in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPFPRO Registry
    Neely, M.
    Bender, S.
    Hellkamp, A. S.
    Todd, J. L.
    Liesching, T.
    Luckhardt, T. R.
    Oldham, J. M.
    Raj, R.
    White, E. S.
    Palmer, S. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [3] Esophageal Motility And Lung Function In Patients With Idiopathic Pulmonary Fibrosis
    Lane-Laratta, C.
    Lazarescu, A.
    Kapasi, A.
    Kalluri, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [4] Obstructive lung function in idiopathic pulmonary fibrosis
    Nishiyama, Osamu
    Tohda, Yuji
    CHRONIC RESPIRATORY DISEASE, 2016, 13 (02) : 206 - 206
  • [5] Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis
    Kawano-Dourado, Leticia
    Funke-Chambour, Manuela
    Wells, Athol U.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (10): : 973 - 973
  • [6] Social and Environmental Determinants of Lung Function in Patients with Idiopathic Pulmonary Fibrosis
    Johannson, K. A.
    Noth, E.
    Collard, H. R.
    Ley, B. J.
    Thakur, N.
    Nathan, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [7] The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis
    Kurashima, Kazuyoshi
    Takayanagi, Noboru
    Tsuchiya, Noriko
    Kanauchi, Tetsu
    Ueda, Miyuki
    Hoshi, Toshiko
    Miyahara, Yosuke
    Sugita, Yutaka
    RESPIROLOGY, 2010, 15 (05) : 843 - 848
  • [8] Lung function status of idiopathic pulmonary fibrosis (IPF) patients and referral for lung transplantation
    Mogulkoc, N
    Brutsche, M
    Egan, JJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A51 - A51
  • [9] Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation
    Mogulkoc, N
    Brutsche, MH
    Bishop, PW
    Greaves, SM
    Horrocks, AW
    Egan, JJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (01) : 103 - 108
  • [10] Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis
    Aussedat, Pierre-Henri
    Chebib, Nader
    Ahmad, Kais
    Glerant, Jean-Charles
    Drevet, Gabrielle
    Grima, Renaud
    Maury, Jean-Michel
    Nasser, Mouhamad
    Thivolet-Bejui, Francoise
    Traclet, Julie
    Turquier, Segolene
    Chalabreysse, Lara
    Tronc, Francois
    Cottin, Vincent
    RESPIRATION, 2021, 99 (12) : 1101 - 1108